Early detection of sepsis

Prof. Sensen from the TU Graz and two scientists present a new technology against breast cancer (F-LU-17).

Whether activating or silencing genes, breaking down defective cells or building new tissue, our body is constantly working to repair itself, even in cases of illness. To fight a disease, our body sends out signals, often long before we ourselves notice the disease. Such signals are, for example, DNA molecules that are released from the body’s own cells, circulate in the blood and are most likely recognised by other cells as a message to stimulate a defence reaction. The identification of these messengers leads to an early detection of sepsis.

Researchers at TU Graz’s Institute of Computational Biotechnology have identified messengers, and together with scientists from the Austrian Centre of Industrial Biotechnology (acib), the Medical University of Graz and CNA Diagnostics GmbH (Grambach, Styria), they are using these endogenous signals (biomarkers), to be able to diagnose sepsis with high accuracy two to three days before the first clinical symptoms occur. The test based on this method could significantly increase the chance of survival of sepsis patients and lower the negative side effects for sepsis survivors. Details on this method have been published in two papers in Journal of Biotechnology (Elsevier).

Classification algorithms serve as a basis

A team, led by TU Graz- and acib-Scientist Christoph W. Sensen, has identified 24 biomarkers with which bacterial- or fungal-induced sepsis can be detected at an earlier stage when compared to the currently used tests, using classification newly developed algorithms. For their work, the bioinformaticians used sequencing data derived from anonymised plasma samples that came from persons diagnosed with sepsis caused by bacteria or fungi, respectively, influenza (a disease with symptoms partly similar to sepsis) or lymphoma, as well as from healthy individuals. The sequencing data formed the basis for the development of the algorithms that were used to identify the markers, thus creating an unprecedented set of markers. This data set can be used to distinguish people in the early stages of sepsis and those with early clinical signs from healthy people and from people with other diseases. Within the patient group for which the markers were developed, the diagnostic accuracy was almost 90 percent in the period from two days before the first clinical signs until two days after diagnosis with the currently used diagnostic methods. In blind studies with patient groups that were not included in the marker development, the accuracy was still up to 81 percent.

Host-based test procedure, approval procedure already underway

The researchers also developed a new form of quantitative real-time PCR test (Polymerase Chain Reaction), a method for amplifying nucleic acids. PCR-based tests are already in use in clinics, e.g. for the detection of the COVID-19 virus in patients. These kind of tests are often used to amplify the DNA or RNA of an infectious agent in a blood, plasma or serum sample, e.g. allowing the direct detection of bacteria or fungi in sepsis patients. In view of the large number of possible pathogen species which might case sepsis however, this is only possible to a very limited extent for sepsis patients and is therefore very imprecise.

The newly developed test focuses on the body’s own signals, which are representative for the onset of sepsis for all bacterial and fungal cases. These can therefore be measured with much higher accuracy and also 2-3 days earlier than the direct detection of pathogens would allow. Approval in the United States has already been applied for and the clinical trial has begun. The work for approval in Europe is just starting. The scientists hope that the tests will soon be used on a large scale.

Further plasma samples sought

In the meantime, data from China shows that even covid-19 patients with severe end-stage disease often had sepsis as a secondary disease. Sensen and his team are all the more interested in cooperating with biobanks such as BBMRI-ERIC and hospitals that are able to provide the team in Graz with plasma samples from Covid-19 patients. On the basis of the sepsis early-detection research programme, the scientists should be able to develop diagnostic tools for the faster identification of high-risk patients and a strategy for early intervention at the first signs of sepsis, which can be used in future pandemics to reduce the consequences of the infection for those affected.

This work is based on following scientific articles:
Ullrich E, Heidinger P, Soh J, Villanova L, Grabuschnig S, Bachler T, Hirschböck E, Sánchez-Heredero S, Ford B, Sensen M, Rosales Rodriguez I, Schwendenwein D, Neumeister P, Zurl CJ, Krause R, Khol JL, Sensen CW: Evaluation of host-based molecular markers for the early detection of human sepsis. 2020, J Biotechnol, 310, p80-88

Grabuschnig S, Soh J, Heidinger P, Bachler T, Hirschböck E, Rosales Rodriguez I, Schwendenwein D, Sensen CW: Circulating cell-free DNA is predominantly composed of retrotransposable elements and non-telomeric satellite DNA. 2020, J Biotechnol, 313, p 48-56.

Picture credits: TU Graz (Lunghammer)